1796: First Vaccination Given

On This Day in Business: May 14, 1796

On May 14, 1796, English physician Edward Jenner inoculated eight-year-old James Phipps with material taken from cowpox lesions on dairy worker Sarah Nelmes. Jenner had observed the belief that people who contracted cowpox were protected against smallpox. He later exposed Phipps to smallpox material, and the boy did not develop the disease. The experiment became the best-known early demonstration of vaccination, a word derived from the Latin term for cow. Although inoculation against smallpox already existed, Jenner’s cowpox method offered a path toward protection without deliberately giving a person smallpox itself.

Jenner published his findings after the Royal Society declined his first submission, distributed material, and encouraged other practitioners to repeat the procedure. Adoption was uneven. Some physicians challenged the evidence, handling and storage were difficult, and public resistance mixed fear, religion, satire, and distrust. Yet smallpox imposed such enormous mortality and economic disruption that successful prevention carried obvious value. Governments, charitable organizations, doctors, and entrepreneurs developed systems for producing vaccine material, training practitioners, recording results, and reaching populations beyond one physician’s household.

Vaccination gradually became public-health infrastructure. Reliable supply required biological quality control and a cold chain; mass programs required financing, clinics, communication, and surveillance. The market for vaccines differed from ordinary consumer goods because one person’s immunity could reduce risk for others. That spillover justified public purchasing and mandates in some jurisdictions, while controversy over safety and authority persisted. Later laboratories developed more standardized vaccines, and coordinated global campaigns ultimately eradicated smallpox, with the World Health Organization declaring the disease eradicated in 1980.

The 1796 experiment matters because it began a scalable preventive model: spend resources before illness to avoid far larger human and economic losses afterward. Its history also contains a serious ethical limitation. A child could not provide modern informed consent, and deliberate exposure to smallpox would be unacceptable under current research standards. Progress therefore includes both the biological idea and the institutions developed to test it responsibly. Vaccine businesses and public agencies must earn trust through evidence, manufacturing consistency, transparent risk communication, and equitable access. Jenner’s observation became transformative only after generations of people turned a local procedure into a dependable system capable of protecting entire populations. Eradication also produced a benefit ordinary sales figures cannot capture: once transmission ended worldwide, later generations no longer needed routine smallpox vaccination. A successful preventive market can shrink by solving the problem it serves. Public procurement and mission-based funding are therefore crucial when maximum social value may eventually eliminate recurring commercial demand.